Literature DB >> 35062059

AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation.

Maliheh Entezari1, Danial Hashemi2, Afshin Taheriazam3, Amirhossein Zabolian4, Shima Mohammadi5, Farima Fakhri5, Mehrdad Hashemi6, Kiavash Hushmandi7, Milad Ashrafizadeh8, Ali Zarrabi9, Yavuz Nuri Ertas10, Sepideh Mirzaei11, Saeed Samarghandian12.   

Abstract

Diabetes mellitus (DM) is considered as a main challenge in both developing and developed countries, as lifestyle has changed and its management seems to be vital. Type I and type II diabetes are the main kinds and they result in hyperglycemia in patients and related complications. The gene expression alteration can lead to development of DM and related complications. The AMP-activated protein kinase (AMPK) is an energy sensor with aberrant expression in various diseases including cancer, cardiovascular diseases and DM. The present review focuses on understanding AMPK role in DM. Inducing AMPK signaling promotes glucose in DM that is of importance for ameliorating hyperglycemia. Further investigation reveals the role of AMPK signaling in enhancing insulin sensitivity for treatment of diabetic patients. Furthermore, AMPK upregulation inhibits stress and cell death in β cells that is of importance for preventing type I diabetes development. The clinical studies on diabetic patients have shown the role of AMPK signaling in improving diabetic complications such as brain disorders. Furthermore, AMPK can improve neuropathy, nephropathy, liver diseases and reproductive alterations occurring during DM. For exerting such protective impacts, AMPK signaling interacts with other molecular pathways such as PGC-1α, PI3K/Akt, NOX4 and NF-κB among others. Therefore, providing therapeutics based on AMPK targeting can be beneficial for amelioration of DM.
Copyright © 2021. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Clinical application; Diabetic complication; Diabetic patients; Glucose metabolism; Insulin resistance

Mesh:

Substances:

Year:  2021        PMID: 35062059     DOI: 10.1016/j.biopha.2021.112563

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

Review 1.  WWOX and metabolic regulation in normal and pathological conditions.

Authors:  Izabela Baryła; Katarzyna Kośla; Andrzej K Bednarek
Journal:  J Mol Med (Berl)       Date:  2022-10-22       Impact factor: 5.606

Review 2.  Recent Advances in the Treatment of Insulin Resistance Targeting Molecular and Metabolic Pathways: Fighting a Losing Battle?

Authors:  Marta Wolosowicz; Slawomir Prokopiuk; Tomasz W Kaminski
Journal:  Medicina (Kaunas)       Date:  2022-03-25       Impact factor: 2.948

3.  Comparative Transcriptome Analysis of Organ-Specific Adaptive Responses to Hypoxia Provides Insights to Human Diseases.

Authors:  Kuo-Sheng Hung; Shiow-Yi Chen; Pang-Hung Hsu; Bo-An Lin; Chin-Hua Hu; Cing-Han Yang; Tun-Wen Pai; Wen-Shyong Tzou; Hsin-Yu Chung
Journal:  Genes (Basel)       Date:  2022-06-19       Impact factor: 4.141

Review 4.  Potential Molecular Targets of Oleanolic Acid in Insulin Resistance and Underlying Oxidative Stress: A Systematic Review.

Authors:  Ángel Fernández-Aparicio; María Correa-Rodríguez; Jose M Castellano; Jacqueline Schmidt-RioValle; Javier S Perona; Emilio González-Jiménez
Journal:  Antioxidants (Basel)       Date:  2022-08-03

Review 5.  Mitophagy: A potential therapeutic target for insulin resistance.

Authors:  Peng Ning; Xiaobo Jiang; Jing Yang; Jiaxing Zhang; Fan Yang; Hongyi Cao
Journal:  Front Physiol       Date:  2022-08-23       Impact factor: 4.755

6.  Jiangtang Sanhao formula ameliorates skeletal muscle insulin resistance via regulating GLUT4 translocation in diabetic mice.

Authors:  Zimengwei Ye; Jinkun Ma; Yage Liu; Bingrui Xu; Xuan Dai; Min Fu; Tian Tian; Xin Sui; Fangfang Mo; Sihua Gao; Dandan Zhao; Dongwei Zhang
Journal:  Front Pharmacol       Date:  2022-09-08       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.